Emerging Strategies in the Immune Checkpoint Inhibitors (ICIs) and the Synergistic Effect of Antibody-Drug Conjugate in Combination with ICIs for Urothelial Carcinoma – Enduring Webcast

Description

Program Description

---

Urothelial carcinoma (UC) carries a poor prognosis and 5-year overall survival of less than 5%, despite standard of care therapy using cisplatin-based chemotherapy and immune checkpoint inhibitors. Antibody-drug conjugates (ADCs) represent a promising new treatment option that utilizes the targeting ability of an antibody to deliver cytotoxic drugs directly to tumors. Many ADCs are currently being investigated for treating UC, with enfortumab vedotin being approved by the US Food and Drug Administration for treating metastatic UC with progressive disease after chemotherapy and/or immune checkpoint inhibitors. Overall, ADCs hold promise as a long-awaited treatment option for UC.

Intended Audience

---

Medical oncologists, urologists, physician assistants, nurse practitioners, and nurses

Commercial Supporter

---

This activity is supported by an educational grant from Gilead Sciences, Inc.